alexa Systematic Review of Monitoring Criteria to Interpret C

Journal of Oncology Medicine & Practice
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Systematic Review of Monitoring Criteria to Interpret CA125 Increments during First-Line Chemotherapy and the Subsequent Follow-Up Period among Patients with Advanced Epithelial Ovarian Cancer

Suher Othman Abu Hassan1*, Dorte L Nielsen2, Malgorzata K Tuxen2, Robert C Bast Jr3 and Gyorgy Soletormos1

1Department of Clinical Biochemistry, North Zealand Hospital, University of Copenhagen, Denmark

2Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark

3Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA

*Corresponding Author:
Suher Othman Abu Hassan, MD
Department of Clinical Biochemistry
University of Copenhagen North Zealand Hospital
Dyrehavevej 29, DK-3400, Hillerød, Denmark
Tel: +45 48 29 48 29; +45 48 29 69 92
E-mail: [email protected]

Received date August 31, 2015; Accepted date September 23, 2015; Published date September 29, 2015

Citation: Abu Hassan SO, Nielsen DL, Tuxen MK, Jr Bast RC, Soletormos G (2015) Systematic Review of Monitoring Criteria to Interpret CA125 Increments during First-Line Chemotherapy and the Subsequent Follow-Up Period among Patients with Advanced Epithelial Ovarian Cancer. J Oncol Med & Pract 1:101. doi:10.4172/jomp.1000101

Copyright: © 2015 Abu Hassan SO, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Background: Optimal clinical management of ovarian cancer patients requires prompt and accurate determination of whether primary or recurrent disease is responding to chemotherapy. If CA125 is to fill this need, we must understand the design and outcomes of clinical trials that have established a correlation between CA125 levels and growth or shrinkage of tumor burden. It is particularly important to define the magnitude of changes in CA125 concentrations that indicate cancer growth and prompt cessation of ineffective therapy. Objective: To review clinical trials which test the ability of CA125 to monitor ovarian cancer growth during chemotherapy for primary disease and detection of recurrence. Methods: The Medline and Embase databases were searched for original articles published in English between January 1982 and May 2014 that evaluated the utility of CA125 for monitoring ovarian cancer growth. Results: CA125 was evaluated in 13 reports during primary therapy and in eight reports during subsequent follow-up. CA125 sensitivity for detecting tumor growth was not reported consistently, but could be calculated from data provided in the articles. During primary therapy, the median sensitivity for recurrence was 60% (range 33%-95%) and during follow-up the median sensitivity was 85% (range 62%-93%). Conclusion: Consistent criteria for indicating disease progression with CA125 could not be defined due to differences in trial design and selection of patients. The most promising criteria should be re-evaluated under similar and standardized conditions. Computer simulation models and change point algorithms may aid in identifying CA125 assessment criteria to be further validated in prospective clinical trials.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version